Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9800783 | 0.88 | AKR1B10 (0.57) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL9245114 | 0.86 | PLK1 (0.45) | CDC25BHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL10455303 | 0.83 | HPGDS (0.52) | CDC25BCYP2C9HIF1AHPGDALDH1A1 | |
| SCHEMBL24895097 | 0.82 | CDC25B (0.56) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL4103770 | 0.81 | CDC25B (0.68) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL1997846 | 0.81 | HTT (0.58) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL10603405 | 0.81 | CDC25B (0.55) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL10527760 | 0.81 | CDC25B (0.55) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL5771713 | 0.81 | CDC25B (0.55) | CDC25BCYP2C9HIF1AHPGDKDM4E | |
| SCHEMBL9806312 | 0.78 | AKR1B10 (0.53) | CDC25BCYP2C9HIF1AHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0627405-B1 | Process for the preparation of methyle 5-bromo-6-methoxy-1-naphthoate | HOECHST AG (DE) | 1997-01-15 | — | — | EP | claimed |
| JP-8268972-A | — | — | None | — | — | JP | disclosed |
| US-6600072-B2 | Cardiovascular disorders; antiischemic agents; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20030013760-A1 | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | BRENDEL JOACHIM (DE) | 2003-01-16 | — | — | US | disclosed |
| EP-0810205-B1 | Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AG (DE) | 2001-03-28 | — | — | EP | disclosed |
| EP-0810205-A1 | Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-03 | — | — | EP | disclosed |
| EP-0627405-B1 | Process for the preparation of methyle 5-bromo-6-methoxy-1-naphthoate | HOECHST AG (DE) | 1997-01-15 | — | — | EP | disclosed |
| JP-H08268972-A | PRODUCTION OF 5-BROMO-6-METHOXY-1-NAPHTHALENE CARBOXYLIC ACID | SUMIKIN CHEM CO LTD | 1996-10-15 | — | — | JP | disclosed |
| EP-0627405-A1 | Process for the preparation of methyle 5-bromo-6-methoxy-1-naphthoate | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-07 | — | — | EP | disclosed |
| EP-0245679-B1 | DEHALOGENATION PROCESS | ETHYL CORPORATION (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0200840-B1 | PROCESS FOR THE PREPARATION OF 6-(LOW)ALKOXY-1-NAPHTHOIC ACIDS, POSSIBLY HALOGENATED AT POSITION 5, AND THE CORRESPONDING ESTERS | DELALANDE S.A. (FR) | 1989-04-05 | — | — | EP | disclosed |
| US-4814497-A | Dehalogenation process | ETHYL CORPORATION (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0245679-A2 | Dehalogenation process | ETHYL CORPORATION (US) | 1987-11-19 | — | — | EP | disclosed |
| US-4705882-A | ALDOSE REDUCTASE INHIBITORS, ANTIDIABETIC AGENTS | AYERST, MCKENNA & HARRISON, INC. (CA) | 1987-11-10 | — | — | US | disclosed |
| EP-0200840-A1 | Process for the preparation of 6-(low)alkoxy-1-naphthoic acids, possibly halogenated at position 5, and the corresponding esters | DELALANDE S.A. (FR) | 1986-11-12 | — | — | EP | disclosed |
| US-4600724-A | ALDOSE REDUCTASE INHIBITOR, DIABETES | AYERST, MCKENNA & HARRISON, INC. (CA) | 1986-07-15 | — | — | US | disclosed |
| US-4568693-A | ANTIDIATBETIC AGENTS | AYERST, MCKENNA & HARRISON, INC. (CA) | 1986-02-04 | — | — | US | disclosed |
| EP-0059596-B1 | N-NAPHTHOYLGLYCINE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1985-04-24 | — | — | EP | disclosed |
| US-4439617-A | TREATING DIABETES, ENZYME INHIBITOR | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-03-27 | — | — | US | disclosed |
| EP-0059596-A1 | N-Naphthoylglycine derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1982-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013760-A1 | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | TNNI3, TNNT2, SCN1B | CDC25B 1908/4885CYP2C9 94/4885HIF1A 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.